» Articles » PMID: 29440502

Influenza-Associated Pediatric Deaths in the United States, 2010-2016

Overview
Journal Pediatrics
Specialty Pediatrics
Date 2018 Feb 15
PMID 29440502
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Influenza-associated pediatric deaths became a notifiable condition in the United States in 2004.

Methods: We analyzed deaths in children aged <18 years with laboratory-confirmed influenza virus infection reported to the Centers for Disease Control and Prevention during the 2010-2011 to 2015-2016 influenza seasons. Data were collected with a standard case report form that included demographics, medical conditions, and clinical diagnoses.

Results: Overall, 675 deaths were reported. The median age was 6 years (interquartile range: 2-12). The average annual incidence was 0.15 per 100 000 children (95% confidence interval: 0.14-0.16) and was highest among children aged <6 months (incidence: 0.66; 95% confidence interval: 0.53-0.82), followed by children aged 6-23 months (incidence: 0.33; 95% confidence interval: 0.27-0.39). Only 31% ( = 149 of 477) of children aged ≥6 months had received any influenza vaccination. Overall, 65% ( = 410 of 628) of children died within 7 days after symptom onset. Half of the children ( = 327 of 654) had no preexisting medical conditions. Compared with children with preexisting medical conditions, children with none were younger (median: 5 vs 8 years old), less vaccinated (27% vs 36%), more likely to die before hospital admission (77% vs 48%), and had a shorter illness duration (4 vs 7 days; < .05 for all).

Conclusions: Each year, influenza-associated pediatric deaths are reported. Young children have the highest death rates, especially infants aged <6 months. Increasing vaccination among children, pregnant women, and caregivers of infants may reduce influenza-associated pediatric deaths.

Citing Articles

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3-8 years with or without previous influenza vaccination histories.

Wen F, Liu S, Zhou L, Zhu Y, Wang W, Wei M Hum Vaccin Immunother. 2025; 21(1):2468074.

PMID: 39993940 PMC: 11853548. DOI: 10.1080/21645515.2025.2468074.


Evaluation of Influenza Vaccine Effectiveness from 2021 to 2024: A Guangdong-Based Test-Negative Case-Control Study.

Zhu L, Han Y, Lu J, Tan J, Liao C, Guo C Vaccines (Basel). 2025; 13(1).

PMID: 39852783 PMC: 11768588. DOI: 10.3390/vaccines13010004.


A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months.

Kothari K, Shah S, Gill V, Ray R, Kumar N, Sanmukhani J Hum Vaccin Immunother. 2024; 20(1):2416329.

PMID: 39445787 PMC: 11508945. DOI: 10.1080/21645515.2024.2416329.


Influenza B Virus Receptor Specificity: Closing the Gap between Binding and Tropism.

Page C, Tompkins S Viruses. 2024; 16(9).

PMID: 39339833 PMC: 11435980. DOI: 10.3390/v16091356.


Influenza B Virus Vaccine Innovation through Computational Design.

Pekarek M, Weaver E Pathogens. 2024; 13(9).

PMID: 39338946 PMC: 11434669. DOI: 10.3390/pathogens13090755.